Factor VIII (FVIII) is an essential blood-clotting protein, also known as anti-hemophilic factor (AHF).In humans, factor VIII is encoded by the F8 gene.
Defects in this gene results in hemophilia A, a recessive X-linked coagulation disorder. Factor VIII is produced in liver sinusoidal cells and endothelial cells outside of the liver throughout the body.
This protein circulates in the bloodstream in an inactive form, bound to another molecule called von Willebrand factor, until an injury that damages blood vessels occurs.
In response to injury, coagulation factor VIII is activated and separates from von Willebrand factor.
The active protein (sometimes written as coagulation factor VIIIa) interacts with another coagulation factor called factor IX.
This interaction sets off a chain of additional chemical reactions that form a blood clot.
Fanhdi is indicated for the prevention and control of bleeding in patients with moderate or severe factor VIII deficiency due to classical hemophilia A.
Fanhdi is not effective in controlling the bleeding of patients with Von Willebrond’s disease.
Active ingredient: Factor VIII (HUMAN)
Presentations: 250 / 500 / 1000 / 1500 ג€“ IU/ML
Powder for solution for injection
| Shelf life | presentation | Packaging material |
| 36 months | ֲ 1 vial (vial with powder) | Vial glass type II |
| 36 months | 1 X 10 ML (with infusion set ) | Syringe prefilled glass type I |
For more information :
http://grifols.com/en/web/spain/bioscience/-/product/fanhdi